Главная страница
Навигация по странице:

  • Приложение А1. Состав рабочей группы Авторы (рабочая группа по подготовке текста рекомендаций)

  • Комитет экспертов

  • артериальная гипертония у взрослых. ВзрослыеID кр62Год утверждения 2016 (пересмотр каждые 3 года)


    Скачать 499.02 Kb.
    НазваниеВзрослыеID кр62Год утверждения 2016 (пересмотр каждые 3 года)
    Дата17.06.2018
    Размер499.02 Kb.
    Формат файлаpdf
    Имя файлаартериальная гипертония у взрослых.pdf
    ТипДокументы
    #47110
    страница9 из 9
    1   2   3   4   5   6   7   8   9
    Список литературы
    1. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014; 13(6):4-11.
    2. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB.
    Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786–1793.
    3. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343–2349.
    4. Fagard RH, Staessen JA, Thijs L, Celis H, Birkenhager WH, Bulpitt CJ, et al. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004; 44:459–464.
    5. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options.
    Executive summary of the report from the 3rd AFNET/EHRA consensus conference.
    Thromb Haemost 2011; 106:1012–1019.
    6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of
    Hypertension 2010; 56:91–98.
    7. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, et al.
    Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol 1995; 25:871–
    878.
    8. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43:731–738.
    9. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur
    Heart J 2010; 31:883–891.echocardiographically determined left ventricular mass in the
    Framingham Heart Study. N Engl J Med 1990; 322:1561–1566.
    10. Cuspidi C, Ambrosioni E, Mancia G, Pessina AC, Trimarco B, Zanchetti A. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens
    2002; 20:1307–1314.
    11. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur
    Heart J 2010; 31:883–891.

    КР62
    63 12. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima- media thickness and risk of stroke and myocardial infarction: the Rotterdam Study.
    Circulation 1997; 96:1432–1437.
    13. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid- artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med
    1999; 340:14–22.
    14. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol
    2010; 55:1600–1607.
    15. Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. Baseline values but nottreatment-induced changes in carotid intimamediathickness predict incident cardiovascular events in treated hypertensive patients: findings in the European
    Lacidipine Study on Atherosclerosis (ELSA). Circulation 2009; 120:1084–1090.
    16. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al.
    Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588–2605.
    17. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236–1241.
    18. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am
    Coll Cardiol 2010; 55:1318–1327.
    19. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S.
    Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39:10–15.
    20. Mattace-Raso FU, vander Cammen TJ, Hofman A, van Popele NM, Bos ML,
    Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113:657–663.
    21. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300:197–208.
    22. De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis 2008; 50:238–263.
    23. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al.
    Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
    Lancet 2010; 375:2073–2081.
    24. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13:2213–2222.
    25. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, et al.
    Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144:172–180.
    26. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986; 39:809–821.
    27. Friedman GD, Selby JV, Quesenberry CP Jr, Armstrong MA, Klatsky AL. Precursors of essential hypertension: body weight, alcohol and salt use and parental history of hypertension. Prev Med 1988; 17:387–402.

    КР62
    64 28. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual datafor one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913.
    29. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012;109:685–692.
    30. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999;
    33:44–52.
    31. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, et al. Prognostic accuracy of day vs. night ambulatory blood pressure: a cohort study. Lancet 2007;
    370:1219–1229.
    32. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer
    DA. Daytime and night-time blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51:55–61.
    33. Ward AM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J
    Hypertens 2012; 30:449–456.
    34. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension 2006; 47:846–853.
    35. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension vs. true normotension: a meta-analysis. J Hypertens 2007;
    25:2193–2198.
    36. Franklin SS, Thijs L, Hansen TW, Li Y, Boggia J, Kikuya M, et al. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta- analysis using the International Database on Ambulatory Blood Pressure Monitoring in
    Relation to Cardiovascular Outcomes population. Hypertension 2012; 59:564–571.
    37. Bobrie G, Clerson P, Menard J, Postel-Vinay N, Chatellier G, Plouin PF. Masked hypertension: a systematic review. J Hypertens 2008; 26:1715–1725.
    38. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.
    Estimation often-year risk of fatal cardiovascular disease in Europe: the SCORE project.
    Eur Heart J 2003; 24:987–1003.
    39. Volpe M, Battistoni A, Tocci G, Agabiti Rosei E, Catapano AL, Coppo R, et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 2012; 30:1056–1064.
    40. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European
    Society of Cardiology, European Atherosclerosis Society and European Society of
    Hypertension. Eur Heart J 1994; 15:1300–1331.
    41. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel
    WB. General cardiovascular risk profile for use in primary care: the Framingham Heart
    Study. Circulation 2008; 117:743–753.
    42. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European
    Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The
    Fifth Joint Task Force of the European Society of Cardiology and Other Societies on
    Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the
    European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur
    Heart J 2012; 33:1635–1701.
    43. Collins R, Mac Mahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272–298.

    КР62
    65 44. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re- appraisal. J Hypertens 2009; 27:923–934.
    45. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
    46. Medical Research Council Working Party. MRC trial on treatment of mild hypertension: principal results. Br Med J 1985; 291:97–104.
    47. Management Committee. The Australian therapeutic trial in mild hypertension. Lancet
    1980; 1:1261–1267.
    48. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al.
    Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121–2158.
    49. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction
    (FEVER) Study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157–2172.
    50. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target <140mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized
    FEVER trial. Eur Heart J 2011; 32:1500–1508.
    51. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000; 355:253–259.
    52. ADVANCE Collaborative Group. Effects of a fixed combination of perindopriland indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;
    370:829–840.
    53. PROGRESS Collaborative Group. Randomised trial of a perindopril based blood- pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033–1041.
    54. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359:1225–1237.
    55. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension.
    Cochrane Database Syst Rev 2009;CD004349.
    56. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 2011;
    154:541–548.
    57. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887–1898.
    58. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT
    Study Group. Lancet 1998; 351:1755–1762.
    59. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J
    1998; 317:703–713.
    60. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24:215–233.
    61. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54:475–481.

    КР62
    66 62. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. high-sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol and triglyceride
    (Cochrane Review). Am J Hypertens 2012; 25:1–15.
    63. He FJ, Mac Gregor GA. How far should salt intake be reduced? Hypertension 2003;
    42:1093–1099.
    64. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al.
    Longterm effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;
    334:885–888.
    65. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1987; 1:647–651.
    66. Cushman WC, Cutler JA, Hanna E, Bingham SF, Follmann D, Harford T, et al.
    Prevention and Treatment of Hypertension Study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med 1998; 158:1197–1207.
    67. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern
    Med 2009; 169:659–669.
    68. Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J
    Clin Nutr 2010; 92:1189–1196.
    69. Estruch R, Ros E, Salas-Salvado J, Covas MID, Corella D, et al., the PREDIMED Study
    Investigators. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet.
    N Eng J Med 2013; 368:1279–1290.
    70. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003;
    42:878–884.
    71. Prospective Studies Collaboration. Body-mass index and causespecific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083–
    1096.
    72. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories. A systematic review and meta-analysis. JAMA 2013;309:71–82.
    73. Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms and cardiovascular risk factors. Hypertension 2005;
    46:667–675.
    74. Fagard RH. Exercise therapy in hypertensive cardiovascular disease.Prog Cardiovasc Dis
    2011; 53:404–411.
    75. Vanhees L, Geladas N, Hansen D, Kouidi E, Niebauer J, Reiner Z, et al. Importance of characteristics and modalities of physical activity and exercise inthe management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II. Eur J Prev Cardiol 2012; 19:1005–1033.
    76. Doll R, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 1994; 309:901–911.
    77. Rosenberg L, Kaufman DW, Helmrich SP, Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313:1511–
    1514.
    78. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O’Connor GT, et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326:1406–1416.
    79. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management: is nice always good? J Hypertens 2012;
    30:660–668.

    КР62
    67 80. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55:399–
    407.
    81. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343–1350.
    82. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA,
    Nathan DM. Reduction in the incidence oftype 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393–403.
    83. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410–1419.
    84. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369:1208–1219.
    85. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffer SM, Solomon SD.
    Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;
    367:2204–2213.
    86. Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Luders S, et al. The angiotensin- receptor blocker candesartan fortreatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741–750.
    87. Fuentes Patarroyo SX, Anderson C. Blood Pressure Lowering in Acute Phase of Stroke,
    Latest Evidence and Clinical Implication. Ther Adv Chronic Dis 2012; 3:163–171.
    88. Rutten FH, Zuithoff NP, Halk F, Grobbee DE, Hoes AW. Beta-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170:880–887.
    89. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106:2422–2427.
    90. Zanchetti A, Crepaldi G, Bond MG, Gallus G, Veglia F, Mancia G, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS: a randomized double-blind trial. Stroke
    2004; 35:2807– 2812.
    91. Ong KT, Delerme S, Pannier B, Safar ME, Benetos A, Laurent S, Boutouyrie P. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J
    Hypertens 2011; 29:1034–1042.
    92. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness attenuation on survival of patients in endstage renal failure. Circulation 2001;
    103:987–992.
    93. Paravastu SC, Mendonca DA, da Silva A. Beta blockers for peripheral arterial disease.
    Eur J Vasc Endovasc Surg 2009; 38:66–70.
    94. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769–1776.
    95. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142:342–351.

    КР62
    68 96. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010;
    363:918–929.
    97. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148:30–48.
    98. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am JMed 2009; 122:290–300.
    99. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelinesforthe prevention ofcardiovasculardisease in women:
    2011 update:aguideline fromthe American Heart Association. J Am Coll Cardiol 2011;
    57:1404–1423.
    100.
    Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al.
    Managementofcardiovascularriskin the peri-menopausal woman: aсonsensus statement of
    European cardiologists and gynaecologists. Eur Heart J 2007; 28:2028–2040.
    101.
    Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of preeclampsia and its consequences: systematic review. BMJ 2001; 322:329–333.
    102.
    Rossi AC, Mullin PM. Prevention ofpre-eclampsiawith low-dose aspirin orvitamins C and E in women at high or lowrisk: a systematic review with meta-analysis.
    Eur J Obstet Gynecol Reprod Biol 2011; 158:9–16.
    103.
    Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al.
    Prevention ofpreeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116:402–414.
    104.
    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R,
    Foidart JM, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Managementof Cardiovascular Diseases during
    Pregnancyof the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147–
    3197.
    105.
    Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens
    2007; 25:747–750.
    106.
    Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069–1075.
    107.
    Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in theAnglo-Scandinavian Cardiac Outcomes Trial. Circulation
    2008; 118:42–48.
    108.
    Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, et al.
    Sequential nephron blockade vs. sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J
    Hypertens 2012; 30:1656–1664.
    109.
    O’Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hyprtension in youth. J Hypertens 2013; 31:649–654.
    110.
    Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, et al.
    Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012;109:685–692.
    111.
    Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re- appraisal. J Hypertens 2009; 27:923–934.
    112.
    Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al.
    Randomised double-blind comparison of placebo and active treatment for older patients

    КР62
    69 with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial
    Investigators. Lancet 1997; 350:757–764.
    113.
    Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic
    Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16:1823–
    1829.
    114.
    SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the
    Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255–3264.
    115.
    The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575–1585. 296. PROGRESS Collaborative
    Group. Randomised trial of a perindopril based blood-pressure-lowering regimen among
    6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;
    358:1033–1041.
    116.
    Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al.
    Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201–1208.
    117.
    Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769–1776.
    118.
    Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD.
    Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of longterm follow-up in the Rheos Pivotal Trial. J Am Soc
    Hypertens 2012; 6:152–158.
    119.
    Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al.,
    ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lowerthan-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-
    LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149–1158.
    120.
    652. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195–2207.
    121.
    Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al.
    Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670–1681.
    122.
    Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849–1860.
    123.
    Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, et al.
    Aspirin is beneficial in hypertensive patients with chronic kidney disease: a posthoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010; 56:956–965.
    124.
    Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.
    Management of hyperglycaemia in type 2 diabetes: a patientcentreed approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55:1577–1596.
    125.
    Bakris GL, Serafidis PA, Weir MR, Dalhof B, Pitt B, Jamerson K, et al.,
    ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events
    (ACCOMPLISH): a prespecified secondary analysis of randomised controlled trial.
    Lancet 2010; 375:1173–1181.
    126.
    Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Sylversten
    JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and

    КР62
    70 beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic
    Diltiazem (NORDIL) study. Lancet 2000; 356:359–365.
    127.
    Deepak L. Bhatt, M.D., M.P.H., David E. Kandzari, M.D.A Controlled Trial of
    Renal Denervation for Resistant Hypertension N Engl J Med 2014; 370:1393-1401 128.
    Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffer SM, Solomon SD.
    Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;
    367:2204–2213.
    129.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al.
    2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the
    Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105–1187.
    Приложение А1. Состав рабочей группы
    Авторы (рабочая группа по подготовке текста рекомендаций)
    1. Чазова И.Е. д.м.н., профессор, член-корр. РАН, председатель Российского медицинского общества по артериальной гипертонии
    2. Ощепкова Е.В. д.м.н., профессор, член Российского медицинского общества по артериальной гипертонии
    3. Жернакова Ю.В. д.м.н., член Российского медицинского общества по артериальной гипертонии
    Комитет экспертов:
    Архипов М.В. (Екатеринбург), Барбараш О.Л. (Кемерово), Галявич А.С. (Казань),
    Гринштейн Ю.И. (Красноярск), Ерегин С.Я. (Ярославль), Карпов Р.С. (Томск), Кисляк
    О.А. (Москва), Кобалава Ж.Д. (Москва), Конради А.О. (Санкт-Петербург), Кухарчук В.В.
    (Москва), Литвин А.Ю. (Москва), Мартынов А.И. (Москва), Медведева И.В. (Тюмень),
    Милягин В.А. (Смоленск), Небиеридзе Д.В. (Москва), Огарков М.Ю. (Новокузнецк),
    Остроумова О.Д. (Москва), Перепеч Н.Б. (Санкт-Петербург), Петричко Т.А. (Хабаровск),
    Подзолков В.И. (Москва), Рогоза А.Н. (Москва), Скибицкий В.В. (Краснодар), Терещенко
    С.Н. (Москва), Ткачева О.Н. (Москва), Трубачева И.А. (Томск), Туев А.В. (Пермь),
    Тюрина Т.В. (Ленинградская область), Фомин В.В. (Москва), Чихладзе Н.М. (Москва),
    Чукаева И.И. (Москва), Шалаев С.В. (Тюмень), Шестакова М.В. (Москва), Шлык С.В.
    (Ростов-на-Дону), Шапошник И.И. (Челябинск), Якушин С.С. (Рязань).
    Все члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта интересов, о которых необходимо сообщить.
    1   2   3   4   5   6   7   8   9


    написать администратору сайта